Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?

Helou J, D'Alimonte L, Quon H, Deabreu A, Commisso K, Cheung P, Chu W, Mamedov A, Davidson M, Ravi A, Loblaw A.

Radiother Oncol. 2017 Jun;123(3):478-482. doi: 10.1016/j.radonc.2017.03.006. Epub 2017 Apr 19.

PMID:
28433413
2.

Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials.

Musunuru HB, Quon H, Davidson M, Cheung P, Zhang L, D'Alimonte L, Deabreu A, Mamedov A, Loblaw A.

Radiother Oncol. 2016 Jan;118(1):112-7. doi: 10.1016/j.radonc.2015.12.020. Epub 2016 Jan 12.

PMID:
26796591
3.

Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer.

Zhang L, Johnson J, Gottschalk AR, Chang AJ, Hsu IC, Roach M 3rd, Seymour ZA.

Pract Radiat Oncol. 2017 Mar - Apr;7(2):e109-e116. doi: 10.1016/j.prro.2016.07.004. Epub 2016 Jul 17.

PMID:
28274401
4.

Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials.

Alayed Y, Cheung P, Pang G, Mamedov A, D'Alimonte L, Deabreu A, Commisso K, Commisso A, Zhang L, Quon HC, Musunuru HB, Helou J, Loblaw DA.

Radiother Oncol. 2018 May;127(2):213-218. doi: 10.1016/j.radonc.2018.03.005. Epub 2018 Mar 24.

PMID:
29588072
5.

Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.

Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J.

Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1099-105.

PMID:
17336216
6.

Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.

King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr.

Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1043-8. doi: 10.1016/j.ijrobp.2008.05.059. Epub 2008 Aug 26.

PMID:
18755555
7.

Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.

Ishiyama H, Kitano M, Satoh T, Kotani S, Uemae M, Matsumoto K, Okusa H, Tabata K, Baba S, Hayakawa K.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):23-8. doi: 10.1016/j.ijrobp.2008.11.006. Epub 2009 Feb 23.

PMID:
19243900
8.

High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.

Fuller DB, Wurzer J, Shirazi R, Bridge SS, Law J, Mardirossian G.

Pract Radiat Oncol. 2015 Nov-Dec;5(6):e615-23. doi: 10.1016/j.prro.2015.04.009. Epub 2015 Jun 6.

PMID:
26059509
9.

Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus.

Kalakota K, Liauw SL.

Urology. 2013 Jun;81(6):1196-201. doi: 10.1016/j.urology.2013.01.047. Epub 2013 Mar 26.

PMID:
23540863
10.

Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.

Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PC.

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1019-34.

PMID:
15752881
11.

"Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.

Marvaso G, Riva G, Ciardo D, Gandini S, Fodor C, Zerini D, Colangione SP, Timon G, Comi S, Cambria R, Cattani F, De Cobelli O, Orecchia R, Jereczek-Fossa BA.

Med Oncol. 2018 May 10;35(6):96. doi: 10.1007/s12032-018-1155-y.

PMID:
29748830
12.

Stereotactic ablative radiotherapy with CyberKnife in the treatment of locally advanced prostate cancer: preliminary results.

Fan CY, Chao HL, Huang WY, Lin CS, Chen CM, Lo CH.

Tumori. 2015 Nov-Dec;101(6):684-91. doi: 10.5301/tj.5000355. Epub 2015 May 21.

PMID:
26045107
13.

Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data.

Loblaw A, Pickles T, Crook J, Martin AG, Vigneault E, Souhami L, Cury F, Morris J, Catton C, Lukka H, Cheung P, Sethukavalan P, Warner A, Yang Y, Rodrigues G; Genitourinary Radiation Oncologists of Canada (GUROC).

Clin Oncol (R Coll Radiol). 2017 Mar;29(3):161-170. doi: 10.1016/j.clon.2016.10.001. Epub 2016 Oct 22.

PMID:
27780694
14.

A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.

Brabbins D, Martinez A, Yan D, Lockman D, Wallace M, Gustafson G, Chen P, Vicini F, Wong J.

Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):400-8.

PMID:
15667959
15.

Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.

Pervez N, Small C, MacKenzie M, Yee D, Parliament M, Ghosh S, Mihai A, Amanie J, Murtha A, Field C, Murray D, Fallone G, Pearcey R.

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):57-64. doi: 10.1016/j.ijrobp.2009.01.048.

PMID:
19395192
16.

High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients.

Pontoriero A, Iatì G, Mondello S, Midili F, Siragusa C, Brogna A, Ielo I, Anastasi G, Magno C, Pergolizzi S, De Renzis C.

Technol Cancer Res Treat. 2016 Feb;15(1):179-85. doi: 10.1177/1533034614566994. Epub 2015 Jan 13.

PMID:
25586517
17.

Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.

Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, Hanscom HN, Laing S, Kim JS, Lei S, Batipps GP, Kowalczyk K, Bandi G, Pahira J, McGeagh KG, Collins BT, Krishnan P, Dawson NA, Taylor KL, Dritschilo A, Lynch JH, Collins SP.

Radiat Oncol. 2013 Mar 13;8:58. doi: 10.1186/1748-717X-8-58.

18.

Late toxicity rates following definitive radiotherapy for prostate cancer.

Ohri N, Dicker AP, Showalter TN.

Can J Urol. 2012 Aug;19(4):6373-80. Review.

19.

Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.

Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, Hunt M, Greenstein S, Amols H.

Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):330-7. doi: 10.1016/j.ijrobp.2007.10.004. Epub 2007 Dec 31.

PMID:
18164858
20.

Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer.

Vesprini D, Catton C, Jacks L, Lockwood G, Rosewall T, Bayley A, Chung P, Gospodarowicz M, Ménard C, Milosevic M, Nichol A, Skala M, Warde P, Bristow RG.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):608-16. doi: 10.1016/j.ijrobp.2011.07.019. Epub 2011 Nov 16.

PMID:
22099034

Supplemental Content

Support Center